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Al~traet Oxidative DNA damage can cause mutation and cell death. We show that L-DOPA, dopamine and 3-O-methyl-DOPA cause xtensive 
oxidative DNA damage in the presence ofH202 and traces of copper ions. 8-Hydroxyguanine is the major product. Iron ions were much less effective 
and manganese ions did not catalyse DNA damage. We propose that copper ion release, in the presence of L-DOPA and its metabolites, may be 
an important mechanism ofneurotoxicity, e.g. in Parkinson's disease and amyotrophic lateral sclerosis. 
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1. Introduction 2. Materials and methods 
Increased levels of oxidative DNA damage have been re- 
ported in Parkinson's disease and Alzheimer's disease and have 
been suggested to be important in their pathology [1,2]. How- 
ever, the mechanism of this damage has not been elucidated. 
Similarly, the familial dominant form of the progressive neuro- 
logical disease amyotrophic lateral sclerosis (ALS) may involve 
oxidative damage, in that it is associated with mutations in the 
gene on chromosome 21 that encodes the copper, zinc-contain- 
ing isoenzyme of superoxide dismutase [3]. Recent experiments 
with transgenic animals uggest that the ALS syndrome is not 
due to lack of SOD activity, but to some toxic property of the 
mutant Cu,ZnSOD enzymes [4]. It may be that the mutant 
enzyme binds copper ions less tightly than usual, so that it is 
released from the enzymes [5]. Copper is neurotoxic, as illus- 
trated by the brain pathology produced in patients with copper 
overload as a result of Wilson's disease [6]. 
The toxicity of released copper may involve free radical dam- 
age [7,8]. Copper ions promote lipid peroxidation [9,10] and 
catalyse formation of highly reactive hydroxyl (OH') radicals 
from hydrogen peroxide (reviewed in [11]). Mixtures of copper 
ions with H202 produce DNA damage; strand breaks [12] and 
chemical changes in the purine and pyrimidine bases, especially 
conversion of guanine into 8-hydroxyguanine [13]. 
However, why should increased availability of copper ions 
be particularly damaging in the nervous ystem? The nervous 
system is rich in L-DOPA and its metabolites, dopamine and 
3-O-methyl-DOPA. We show here that exposure of DNA to 
these products in the presence of even traces of copper ions 
causes massive DNA base damage, and we propose that this 
could be a cytotoxic mechanism when traces of copper are 
liberated in the brain, e.g. as a result of cell injury [7,8] and 
perhaps in ALS [5]. 
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Abbreviations." 5-OH uracil, 5,hydroxyuracil; 5-OH, Me Uracil, 5- 
(hydroxymethyl)uracil: FapyAdenine, 4 6-diamino-5-formamido pyri-
midine; OH Ade, 8-hydroxyadenine; FapyGuanine, 2,6-diamino-4- 
hydroxy-5 formamidopyrimidine; 8-OH guanine, 8-hydroxyguanine. 
2.1. Materials 
L-DOPA, dopamine, 3-O-methyl-DOPA, 1,10 o-phenanthroline, ble- 
omycin sulphate, calf thymus DNA, 8-azaadenine, 6-azathymine, 
8-bromoadenine, 5-hydroxyuracil (isobarbituric acid),4,6-diamino-5- 
formamidopyrimidine (FAPy-adenine), 2,5,6-triamino-4-hydroxypy- 
rimidine and 5-(hydroxymethyl)uracil were purchased from Sigma 
Chemical Co (Poole, Dorset, UK). 2-Amino-6,8-dihydroxypurine (8- 
hydroxyguanine) was from Aldrich (Gillingham, Dorset, UK). Silyla- 
tion grade acetonitrile and bis(trimethylsilyl) trifluoracetamide 
(BSTFA) (containing 1% trimethylchlorosilane) w re obtained from 
Pierce Chemical Co (Rockford, IL, USA). 6-Amino-8-hydroxypurine 
(8-hydroxyadenine) wassynthesised bytreatment of 8-bromoadenine 
with concentrated formic acid (95%) at 150°C for 45 min and purified 
by crystallisation from water. 2,6-Diamino-4-hydroxy-5-formamidopy- 
rimidine (FAPy- guanine) was synthesised by treatment of 2,5,6-tri- 
amino-4-hydroxypyrimidine with concentrated formic acid and recrys- 
tallised from water. Dialysis membranes with a molecular mass cut off 
of 3500 were purchased from Spectrum supplied by Pierce Chemical 
Co. Distilled water passed through a purification system (Elga, High 
Wycombe, Bucks, UK) was used for all purposes. 
2.2. Treatment of DNA 
The amount of DNA recovered for each sample after dialysis was 
determined spectrophotometrically at 260 nm (A2~0 of 1.0 = 50/lg 
DNA/ml). One nmol of 6-azathymine and 2 nmol of 8-azaadenine w re 
added as internal standards toeach aliquot containing 0.1 mg of DNA. 
Aliquots were then lyophilized. 
2.3. DNA hydrolysis 
DNA aliquots were hydrolysed with 0.5 ml formic acid (60% v/v) in 
evacuated and sealed tubes for 45 min at 150°C. Samples were lyophil- 
ised and then trimethylsilyated in poly(tetrattuorethylene)-capped hy- 
povials (Pierce) with 0.1 ml of a BSTFA/acetonitrile (4:1, v/v) mixture 
by heating at 90°C for 60 min. 
2.4. Gas chromatography/mass spectrometry 
Derivatized samples were analysed by a Hewlett-Packard 5971A 
mass selective detector interfaced with a Hewlett-Packard 5890II gas 
chromatograph equipped with an automatic sampler and a computer 
work station. The injection port and the GC-MS interface were kept 
at 220°C and 280°C, respectively. Separations were carried out on a 
fused silica capillary column (12 m x 0.20 mm i.d) coated with cross- 
linked 5% phenylmethylsiloxane (film thickness 0.33 pm) (Hewlett- 
Packard). Helium was the carder gas with a constant flow rate of 0.91 
ml/min. Derivatized samples (4 HI) were injected into the GC injection 
port using the split mode. A split ratio of 8 : 1 was used, resulting in 
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approximately 0.5 gg of DNA loaded on to the column. The column 
temperature was increased from 145 to 1900C at 10°C/rain after 2 min 
at 145°C. Subsequently he temperature was further increased from 
190°C to 2700C at 30°C/min and then kept at 270°C for 2 min. Se- 
lected-ion monitoring was performed using the electron-ionisation 
mode at 70 eV with the ion source maintained at 180°C. 
2.5. Assay of metal ions 
Brain tissue from control subjects who died from non-neurological 
disorders and from patients who died from clinically diagnosed Parkin- 
son's disease was obtained from the Parkinson's Disease Society Brain 
Bank (University Department ofClinical Neurology, Institute of Neu- 
rology, London). 
At autopsy, brains were removed and divided midsagittally. One half 
of the brain was immediately frozen at -70°C for biochemical nalysis. 
The substantia nigra, putamen and cerebellum were then dissected on 
a refrigerated platform (-11°C) from the frozen brain using standard 
dissection techniques The dissected brain tissue was stored at -700C 
until analysis. Samples (20-30 mg) from these parts of the brain were 
weighed into Eppendorf tubes. One ml of double distilled eionized 
water was added and the tissue was dispersed by pulse sonication. 
Control samples consisting of 1 ml of water only were subjected tothe 
same treatment. The homogenates were then assayed for iron and 
copper ions catalytic for free radical reactions using the bleomycin and 
copper-phenanthroline assays respectively asdescribed in[14]. Homo- 
genised brain samples peroxidise r adily (reviewed in [15]) and create 
high blanks in the phenanthroline assay. In order to correct for this, 
butylated hydroxytoluene (0.02% w/v, final concentration) was in- 
cluded in all copper-phenanthroline assays. Calibration experiments 
were performed in the presence of BHT, which had little effect on the 
assay. 
3. R ~  
3.1. Oxidative DNA damage," effect of  L-DOPA and its 
metabolites 
Oxidative DNA base damage was measured using gas 
chromatography/mass spectrometry [16], which allows determi- 
nation of multiple products of free radical attack on the DNA 
bases [16-18]. Exposure of DNA to L-DOPA, dopamine or 
3-O-methyl-DOPA did not increase oxidative base damage 
over that present in the commercial DNA itself (Table 1). Sim- 
ilarly, exposure of the DNA to copper ions or to H20 2 alone 
had little effect (Table 2). As expected [13], Cu2+/H202 caused 
some DNA base damage, which was greatly accelerated in the 
presence of ascorbic acid. However, when DOPA, dopamine 
or 3-O-methyl-DOPA were incubated with DNA, Cu 2+ and 
H202, there was devastating DNA base damage, to an extent 
we have never observed in our previous work [17,18] (Table 2, 
last 3 columns). By contrast, mixtures of iron ions with H202 
and dopamine, L-DOPA or 3-O-methyl-DOPA produced much 
less oxidative DNA base damage (Table 3). 
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Table 1 
Lack of effect of L-DOPA, dopamine or 3-O-methyl-DOPA on oxi- 
dative damage to the bases of DNA 
Base product DNA DNA + DNA + DNA + 
(nmoFmg DNA) only DOPA- L-DOPA Me 
MINE DOPA 
5-OH Uracil 0.036 0.035 0.045 0.036 
5-OH, Me Uracil 0.013 0.023 0.014 0.016 
FAPy Adenine 0.190 0.188 0.224 0.339 
8-OH Adenine 0.130 0.055 0.106 0.140 
FAPy Guanine 0.579 0.385 0.591 0.497 
8-OH Guanine 0.104 0.050 0.201 0.141 
Total damage 1.052 0.736 1.181 1.169 
DOPA and its metabolites were present at final concentrations of 1 mM. 
Figs. 1 and 2 show the effect of Cu 2+ concentration on 
oxidative DNA damage in the presence of dopamine, L-DOPA 
or 3-O-methyl-DOPA. Significant increases were seen at cop- 
per ion concentrations as low as 1/tM. In all cases, the major 
base damage product was 8-hydroxyguanine (Table 2 and Fig. 2). 
Manganese ions are known to promote oxidation of cat- 
echolamines [19]. However, replacing copper ions by Mn 2÷ ions 
in any of the above systems did not significantly increase DNA 
damage (Table 4). 
3.2. Copper and iron availability in brain 
Brain tissue was homogenised and the availability of iron and 
copper ions catalytic for free radical reactions was measured 
as described in section 2. Table 5 shows that significant levels 
of both metal ions could be measured, in all 3 brain regions 
tested, from both parkinsonian brain and control brains 
matched for sex, age at time of death, storage time and other 
parameters of tissue handling. 
4. Discussion 
We show here that copper ions are very powerful inducers 
of oxidative damage to DNA in the presence of H202 and 
DOPA, dopamine or 3-O-methyl-DOPA. Hydrogen peroxide 
is a normal metabolite in brain, produced by several enzymes, 
including SOD and monoamine oxidase [3,20]. Our data using 
the phenanthroline assay (Table 5) show that copper ion con- 
centrations in injured brain, although low, are at the level that 
could promote such damage and small increases in copper ions 
availability could produce large increases in damage (Figs. 1 
and 2). Thus if copper ions were released from mutant 
Cu,ZnSOD enzymes in ALS, then damage could increase 
Table 2 
Damage to DNA bases by copper iordH202 systems in the presence of ascorbate, dopamine, L-DOPA or 3-O-methyl-DOPA 
Base product DNA DNA DNA + Cu 2÷ plus DNA DNA + DNA + Cu 2÷, HzO2 plus 
(nmol/mg) Only Cu 2+ H202 Cu 2+, 
ASC Dopamine L-DOPA MeDOPA H202 ASC Dopamine L-DOPA MeDOPA 
5-OH Uracil 0.035 0.137 0.349 0.241 0.261 0.267 0.254 0.284 3.544 17.943 21.631 19.441 
5-OH, Me Uracil 0.010 0.025 0.046 0.101 0.141 0.099 0.015 0.039 0.348 0.741 0.911 0.732 
FAPy Adenine 0.146 0.254 0.518 0.291 0.582 0.563 0.178 0.471 2.082 7.811 11.414 8.914 
8-OH Adenine 0.095 0.221 0.517 1.431 1.694 1.563 0.198 0.604 8.076 28.141 31.914 30.631 
FAPy Guanine 0 .682 0.589 2.319 1.561 1.714 1.704 0.561 0.659 6.972 24.816 22.764 20.119 
8-OH Guanine 0.177 0.100 1.554 2.714 3.119 3.431 0.198 0.531 55.640 283.141 362.671 351.617 
Total damage 1.145 1.326 5.303 6.339 7.511 7.627 1.404 2.588 76.662 362.593 451.305 431.454 
Reaction mixtures contained buffer, calf-thymus DNA, H202 (2.8 mM) CuSO4 (100/IM) and other products at the final concentrations i dicated: 
ascorbate (100/tM), L-DOPA (100/IM), Dopamine (100/~M), 3-O-Methyl-DOPA (100/.tM). 
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Fig. 1. Effect of increasing copper ion concentrations on DNA base damage in the presence of H202 and L-DOPA, dopamine or 3-O-methyl-DOPA 
(all at 1 mM final concentration). CuSO4 was present at the final concentrations i dicated. FaPy guanine v; OH adenine ; OH uracil o; FAPy adenine 
~; OH, Me uracil ~. A, dopamine; B, L-DOPA; C, 3-O-methyl-DOPA. 
markextly. Levels of L-DOPA and its mctabolites in brain are 
sufficient o allow the reactions we have described to occur 
[20,21]. There appeared to be no significant difference in copper 
ion levels between ormal and parkinsonian brain, although 
the variability in results makes this conclusion tentative because 
of the small number of samples we have used. 
Table 3 
Damage to DNA bases by iron ion-containing systems 
Base product DNA DNA DNA + Fe 3+ plus 
(nmol/mg) Only Fe 3+ 
ASC Dopamine L-DOPA MoDOPA H202 
DNA + Fe 3÷, H202 plus 
ASC Dopamine L-DOPA MeDOPA 
5-OH Uracil 0.036 0.149 0.281 0.151 0.167 0.190 1.015 1.688 0.381 0.404 0.356 
5-OH,Me Uracil 0.013 0.070 0.094 0.096 0.136 0.104 0.077 0.147 0.142 0.143 0.116 
FAPy Adenine 0.190 1.133 1.445 1.431 1.697 1.506 4.836 4.910 2.291 2.416 2.396 
8-OH Adenine 0.130 0.311 0.436 0.468 0.471 0.490 1.011 1.325 0.941 1.316 1.104 
FAPy Guanine 0.579 0.776 0.871 0.986 1.631 1.143 0.841 7.514 4.041 10.461 5.914 
8-OH Guanine 0.104 2.040 3.773 1.843 1.948 2.046 5.738 20.466 15.941 16.114 16.748 
Total damage 1.052 4.479 6.900 4.975 6.050 5.479 13.518 36.050 23.737 30 .854  26.634 
Experiments were carried out as described in the legend to Table 2, except hat CuSO4 was replaced by FeC13, 
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Table 4 
Lack of damage to DNA bases by manganese ion-containing systems 
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Base product DNA DNA + DNA + Mn 2+ plus DNA + Mn 2+, H202 plus 
(nmol/mg) Only Mn 2+ 
ASC Dopamine L-DOPA MeDOPA H202 ASC Dopamine L-DOPA MeDOPA 
5-OH Uracil 0.031 0.040 0.034 0.024 0.027 0.103 0.069 0.073 0.070 0.094 0.071 
5-OH,Me Uracil 0.014 0.012 0.021 0.011 0.018 0.024 0.021 0.017 0.018 0.034 0.016 
FAPy Adenine 0.231 0.247 0.381 0.464 0.394 0.463 0.333 0.479 0.474 0.391 0.446 
8-OH Adenine 0.111 0.250 0.112 0.060 0.169 0.261 0.233 0.286 0.221 0.351 0.247 
FAPy Guanine 0.715 1.253 0.936 1.016 0.970 1.827 1.941 2.155 1.920 2.043 2.001 
8-OH Guanine 0.205 0.649 0.324 0.230 0.271 0.331 0.874 0.564 0.499 1.149 0.508 
Total damage 1.307 2.451 1.808 1.805 1.849 3.009 3.471 3.574 3.202 4.062 3.289 
Experiments were carried out as described in the legend to Table 2, except that CuSO4 was replaced by MnS04 and the compounds were tested at 
the final concentration f 1 raM. 
The pattern of DNA damage observed is characteristic of
attack by highly-reactive hydroxyl (OH') radicals, giving a mul- 
tipLicity of base damage products [16-18]. Many of these are 
known to be mutagenic or to interfere with DNA replication 
[22,23]. Excessive DNA damage can lead not only to mutations 
but also to cell death, e.g. by NAD + depletion [24]. The major 
product was 8-hydroxyguanine; this product may be favoured 
because of binding of Cu 2÷ ions to GC-rich regions in DNA 
[25]. Indeed, the binding of copper ions to DNA may facilitate 
their interaction with L-DOPA and its metabolites in a way that 
greatly accelerates free radical production [26]. 
Iron ions also promoted oxidative DNA damage in the pres- 
ence of L-DOPA and its metabolites, although to a much lesser 
extent han Cu 2+ (Table 3). However, our data with the bleo- 
mycin assay show that comparable amounts of iron and copper 
ions are released from injured human brain tissue. Gutteridge 
et al. [27] reported that 19-25 nmol/g of bleomycin-detectable 
iron is present in gerbil brain tissue, results comparable to our 
human brain samples (Table 5). It seems, therefore, that iron- 
dependent reactions might be of lesser significance than copper- 
dependent reactions in vivo. 
Although manganese ions are known to promote catechol- 
amine oxidation, no oxidative DNA base damage was observed 
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Fig. 2. Effect of increasing copper ion concentrations on8-hydroxygua- 
nine concentrations in DNA in the pre-~nce of H202 and L-DOPA, 
dopamine or 3-O-methyl-DOPA (all at 1 mM final concentrations). 
Table 5 
Measurement of iron and copper ions catalytic for free radical reactions 
in human brain tissue 
Brain Region Iron detected in
bleomycin assay 
Copper detected in
phenanthroline assay 
pM in nmol/g /zM in nmol/g 
assay tissue assay tissue 
Cerebellum 
normal 0.72 _+ 0.02 26 -+ 5 (6) 0.60 _+ 0.35 21 4. 10 (6) 
PD 0.71_+0.16 25_+7 (6) 0.83_+0.21 294-7 (6) 
Median putamen 
normal 1.86 -+ 0.57 61 _+ 20 (6) 0.45 -+ 0.37 21 4- 16 (6) 
PD 1.19 -+ 0.54 45 _+ 17 (6) 1.53 _+ 0.93 56 4- 30 (6) 
Substantia nigra 
normal 1.27 -+ 0.73 51 -+ 27 (3) 1.20 _+ 0.80 53 -+ 48 (3) 
PD 0.59 _+ 0.07 36 -+ 23 (3) 1.15 _+ 1.15 63 4- 48 (2) 
A known mass of brain tissue (20-30 mg) was dissected from the regions 
shown above and sonicated in 1 ml of double distilled water. Copper 
and iron determinations were then carried out immediately on the 
homogenate asdescribed in section 2. Controls consisting of 1 ml of 
distilled water taken through the same procedure had no detectable iron 
or copper. Results are mean _+ S.D., n in parentheses. PD = Parkin- 
son's disease. 
in this system. This may be because Mn 2+ ions will not convert 
H202 to OH" [28]. Our data may explain the elevated DNA 
damage seen in several neurodegenerative diseases, and could 
be particularly relevant to Parkinson's disease. Treatment of 
this disease with L-DOPA will raise levels of L-DOPA, dopam- 
ine and 3-O-methyl-DOPA in the brain [20,21]. Thus recent 
reports that levels of 8-hydroxyguanine arcincreased in DNA 
from parkinsonian substantia nigra [21] do not necessarily 
mean that the disease itself increases oxidative DNA damage, 
but could be due (in whole or in part) to the treatment. 
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